{"analyses":[{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.72","groupDescription":"Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.00001","paramType":"Hazard Ratio (HR)","paramValue":"0.58","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.47","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.72","groupDescription":"Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.00001","paramType":"Hazard Ratio (HR)","paramValue":"0.58","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupDescription":"Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.75869","paramType":"Hazard Ratio (HR)","paramValue":"0.97","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"2.9","value":"2.8"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"6.9","value":"5.5"},{"groupId":"OG002","lowerLimit":"2.9","upperLimit":"6.9","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"279"},{"groupId":"OG002","value":"277"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the first documented disease progression, based on blinded Independent Radiology plus Oncology review (IRO) using RECIST 1.1, or death due to any cause, whichever occurred first. Disease progression was defined as a 20% or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm or the appearance of new lesions. The primary analysis of PFS was performed at the time of the first protocol pre-specified statistical analysis, with data cut-off of 03-Sep-2014.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).","id":"OG000","title":"Ipilimumab"},{"description":"Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.","id":"OG001","title":"Pembrolizumab Q2W"},{"description":"Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.","id":"OG002","title":"Pembrolizumab Q3W"}],"paramType":"MEDIAN","populationDescription":"The ITT population, comprising all participants as randomized to a study arm.","reportingStatus":"POSTED","timeFrame":"Up to approximately 12 months (through first pre-specified statistical analysis cut-off date of 03-Sep-2014)","title":"Progression-free Survival (PFS) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Radiology Plus Oncology Review (IRO)","type":"PRIMARY","unitOfMeasure":"Months"}